CompletedPhase 1

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

NCT02890069

What is this trial?

Generating plain-language summary...

Generating eligibility summary...

Summarizing study design...

Primary location

UCLA Santa Monica Hematology / Oncology SC

Santa Monica, California, United States

+24 additional locations

Save this trial

UCLA Santa Monica Hematology / Oncology SCSanta Monica, California, United States
Sidney Kimmel Comprehensive Cancer CenterBaltimore, Maryland, United States
Massachusetts General HospitalBoston, Massachusetts, United States
The Regents of the University of MichiganAnn Arbor, Michigan, United States
Washington University Medical School SCSt Louis, Missouri, United States
University of Texas MD Anderson Cancer CenterHouston, Texas, United States
UT Health San Antonio Mays Cancer CenterSan Antonio, Texas, United States
Huntsman Cancer InstituteSalt Lake City, Utah, United States
Seattle Cancer Care AllianceSeattle, Washington, United States
Novartis Investigative SiteJena, Germany
Novartis Investigative SiteUlm, Germany
Novartis Investigative SiteWürzburg, Germany
Novartis Investigative SiteAmsterdam, Netherlands
Novartis Investigative SiteLeiden, Netherlands
Novartis Investigative SiteRotterdam, Netherlands
Novartis Investigative SiteUtrecht, Netherlands
Novartis Investigative SiteSeoul, Korea, South Korea
Novartis Investigative SiteSeoul, South Korea
Novartis Investigative SiteBarcelona, Catalonia, Spain
Novartis Investigative SitePamplona, Navarre, Spain
Novartis Investigative SiteMadrid, Spain
Novartis Investigative SiteTaipei, Taiwan
Novartis Investigative SiteSutton, Surrey, United Kingdom
Novartis Investigative SiteManchester, United Kingdom
Novartis Investigative SiteOxford, United Kingdom